دورية أكاديمية
أعرض في EDS

A Delphi panel to build consensus on assessing disease severity and disease progression in adult patients with hypophosphatasia in the United States.

التفاصيل البيبلوغرافية
العنوان: A Delphi panel to build consensus on assessing disease severity and disease progression in adult patients with hypophosphatasia in the United States.
المؤلفون: Dahir KM; Division of Endocrinology and Metabolism, Vanderbilt University Medical Center, 1215 21st Ave S Suite 8210, Nashville, TN, 37232, USA. kathryn.dahir@vumc.org., Rush ET; Division of Clinical Genetics, Children's Mercy Kansas City, 2401 Gillham Rd, Kansas City, MO, 64108, USA. etrush@cmh.edu.; Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. etrush@cmh.edu.; Department of Internal Medicine, University of Kansas School of Medicine, Kansas City, KS, USA. etrush@cmh.edu., Diaz-Mendoza S; OPEN Health Group, Marlow, UK., Kishnani PS; Division of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
المصدر: Journal of endocrinological investigation [J Endocrinol Invest] 2024 Jun; Vol. 47 (6), pp. 1487-1497. Date of Electronic Publication: 2024 Jan 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1720-8386 (Electronic) Linking ISSN: 03914097 NLM ISO Abbreviation: J Endocrinol Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 2014- : Berlin : Springer
Original Publication: Milano, Published for the Italian Society of Endocrinology by Editrice Kurtis.
مواضيع طبية MeSH: Hypophosphatasia*/diagnosis , Delphi Technique* , Disease Progression* , Consensus* , Severity of Illness Index*, Humans ; Adult ; United States/epidemiology ; Female ; Male ; Health Personnel ; Surveys and Questionnaires
مستخلص: Background: Hypophosphatasia (HPP) is an inborn error of metabolism with a variable presentation. We conducted a modified Delphi panel to obtain expert consensus on knowledge gaps regarding disease severity and progression in adult patients with HPP.
Methods: Healthcare professionals (HCPs) with experience managing adult patients with HPP were recruited to participate in a 3-round Delphi panel (round 1: paper survey and 1:1 interview; rounds 2-3: email survey). Panelists rated the extent of their agreement with statements about disease severity and progression in adult patients with HPP. Consensus was defined as ≥ 80% agreement.
Results: Ten HCPs completed round 1; nine completed rounds 2 and 3. Consensus was reached on 46/120 statements derived from steering committee input. Disease severity markers in adult patients with HPP can be bone-related (recurrent/poorly healing fractures, pseudo-fractures, metatarsal fractures, osteomalacia) or involve dentition or physiologic/functional manifestations (use of mobility devices/home modifications, abnormal gait, pain). Disease progression markers can include recurrent/poorly healing low-trauma fractures, development of ectopic calcifications, and/or impairment of functional activity. Panelists supported the development of a tool to help assess disease severity in the clinic and track changes in severity over time. Panelists also highlighted the role of a multidisciplinary team, centers with expertise, and the need to refer patients when disease severity is not clear.
Conclusions: These statements regarding disease severity, progression, and assessment methods address some knowledge gaps in adult patients with HPP and may be helpful for treating HCPs, although the small sample size affects the ability to generalize the healthcare provider experience.
(© 2024. The Author(s).)
References: J Endocr Soc. 2020 Oct 14;4(12):bvaa151. (PMID: 33204932)
BMJ Open. 2020 Oct 10;10(10):e035182. (PMID: 33039984)
Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:380-8. (PMID: 23858621)
Orphanet J Rare Dis. 2021 Oct 28;16(1):452. (PMID: 34711245)
Bone. 2021 Jan;142:115695. (PMID: 33069919)
Int J Obes (Lond). 2019 Dec;43(12):2573-2586. (PMID: 30655580)
Orphanet J Rare Dis. 2019 Aug 16;14(1):201. (PMID: 31419999)
J Bone Joint Surg Am. 1986 Sep;68(7):981-90. (PMID: 3745261)
Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):230-234. (PMID: 29263739)
J Am Geriatr Soc. 1991 Feb;39(2):142-8. (PMID: 1991946)
Nat Rev Endocrinol. 2016 Apr;12(4):233-46. (PMID: 26893260)
Orphanet J Rare Dis. 2019 Apr 25;14(1):85. (PMID: 31023354)
J Bone Miner Res. 2017 Oct;32(10):1977-1980. (PMID: 28731215)
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. (PMID: 12091180)
JBMR Plus. 2019 Mar 01;3(6):e10131. (PMID: 31346563)
Metabolism. 2016 Oct;65(10):1522-30. (PMID: 27621187)
Front Endocrinol (Lausanne). 2023 Mar 27;14:1138599. (PMID: 37051203)
Mol Genet Metab Rep. 2020 Oct 21;25:100661. (PMID: 33101980)
Orphanet J Rare Dis. 2022 Dec 14;17(1):435. (PMID: 36514157)
Mol Genet Metab. 2017 Sep;122(1-2):4-17. (PMID: 28888853)
Bone. 2015 Jun;75:229-39. (PMID: 25731960)
BMJ. 1995 Aug 5;311(7001):376-80. (PMID: 7640549)
J Bone Miner Res. 2020 Nov;35(11):2171-2178. (PMID: 32654183)
Arch Intern Med. 1981 May;141(6):727-31. (PMID: 7235780)
J Bone Miner Res. 2017 Apr;32(4):667-675. (PMID: 28084648)
Mol Genet Metab. 2015 Nov;116(3):215-20. (PMID: 26432670)
JBMR Plus. 2020 Aug 04;4(9):e10395. (PMID: 32995696)
Ann Hum Genet. 2011 May;75(3):439-45. (PMID: 21488855)
J Bone Joint Surg Br. 1979 Feb;61(1):82-4. (PMID: 422640)
Arthritis Rheum. 2005 Feb 15;53(1):61-6. (PMID: 15696560)
World J Methodol. 2021 Jul 20;11(4):116-129. (PMID: 34322364)
Age Ageing. 2003 May;32(3):315-20. (PMID: 12720619)
فهرسة مساهمة: Keywords: Consensus; Delphi; Hypophosphatasia
تواريخ الأحداث: Date Created: 20240118 Date Completed: 20240601 Latest Revision: 20240603
رمز التحديث: 20240603
مُعرف محوري في PubMed: PMC11142979
DOI: 10.1007/s40618-023-02256-4
PMID: 38236379
قاعدة البيانات: MEDLINE
الوصف
تدمد:1720-8386
DOI:10.1007/s40618-023-02256-4